Zogenix Launches Dravet Syndrome Community Photo Sharing Charitable Campaign and Contest to Benefit the Dravet Syndrome Foundation and the Epilepsy Foundation

EMERYVILLE, Calif., May 19, 2021 /PRNewswire/ — Zogenix, a global biopharmaceutical company developing rare disease therapies, today launched the FINTEPLA Photo…

EMERYVILLE, Calif., May 19, 2021 /PRNewswire/ — Zogenix, a global biopharmaceutical company developing rare disease therapies, today launched the FINTEPLA Photo Diary, a community sharing, charitable campaign and contest. To participate in the charitable campaign and contest, Zogenix is asking the Dravet syndrome community to share photos of their everyday moments in life with fewer seizures on FINTEPLA® (fenfluramine) from now through June 9, 2021. From June 21July 19, 2021, each time a member of the public «Likes» or shares a featured photo in the FINTEPLA Photo Diary hosted on the FINTEPLA Facebook page, Zogenix will proudly donate $25 to support advocacy organizations that serve the Dravet syndrome community in the United States (US). Up to $50,000 will be donated and equally divided between the Dravet Syndrome Foundation and the Epilepsy Foundation, in support of the work they do for those impacted by Dravet.

The FINTEPLA Photo Diary campaign and contest is powered by FINTEPLA families and aims to celebrate everyday moments in life with fewer seizures, as well as the Dravet syndrome community. These moments are meaningful, because Dravet syndrome is a rare, catastrophic form of epilepsy in which a person may have multiple seizures per day coupled with significant developmental, motor, and behavioral impairments that severely impact patients, families, and caregivers.

FINTEPLA is a prescription medicine approved by the US Food and Drug Administration (FDA) in 2020 to treat the seizures associated with Dravet syndrome in patients 2 years of age and older. In a clinical study, when added to other antiepileptic medicines, FINTEPLA was shown to reduce monthly seizures by 79% on average in patients taking 0.7 mg/kg/day of FINTEPLA, compared to a 16% reduction in patients taking other antiepileptic medicines and placebo. Due to the risk of heart valve problems and pulmonary arterial hypertension, FINTEPLA is available only through the FINTEPLA REMS Program in the US. Please read Important Safety Information, including Boxed Warning below.

«We are constantly inspired by the Dravet community and members’ support for one another. These families have taught us the importance of capturing everyday moments that can occur when seizures do not. We feel these moments are worth recognizing,» said Ashish Sagrolikar, Chief Commercial Officer at Zogenix, Inc. «At Zogenix, we are committed to working alongside the Dravet syndrome and the larger epilepsy community to celebrate more everyday moments, and we hope that the FINTEPLA Photo Diary will inspire others to do the same.»

In addition to making charitable contributions to advocacy organizations, three families with the highest total number of «Likes» and shares will also win prizes. The FINTEPLA family whose featured photo receives the most «Likes» and shares from the public will earn an outdoor photo shoot with a local, professional photographer. Two runner-up submissions will receive an iPad to capture even more everyday moments between seizures.

«With my daughter’s seizures more controlled, we’re capturing even more moments as a family,» said Bethany Goering, a caregiver whose 12-year-old daughter has Dravet syndrome. «The FINTEPLA Photo Diary campaign and contest is an opportunity for us to share the hope that we have in between seizures. We’re excited that our participation will support advocacy groups helping others with Dravet syndrome.»

The FINTEPLA Photo Diary Charitable Campaign and Contest is open only to residents of the US. Campaign details can be found on the FINTEPLA Facebook page and at DravetPhotoDiary.com.

Through June 9, 2021: Call for Photo Entries

  • To submit photos, US families who have a child with a Dravet syndrome diagnosis and a current prescription for FINTEPLA can visit the FINTEPLA Facebook page and go to the FINTEPLA Photo Diary tab. Mobile users may visit DravetPhotoDiary.com. Once on the campaign page, families will be required to complete a short registration form.
  • Families may submit 5-7 photos showing everyday moments in life with fewer seizures with their own captions to enter the contest.

June 21July 19, 2021: Sharing and «Liking» to Support Advocacy Groups

  • Everyone is encouraged to «Like» and share featured photos in the Photo Diary. (Visitors to the site may log in to «Like» or share photos once per day.)
  • For each «Like» or share of a featured photo, Zogenix will donate $25 to advocacy groups that support the Dravet syndrome community, up to $50,000 in total.
  • The three featured photos with the highest total number of «Likes» and shares will be contacted by Zogenix and announced on or around August 9, 2021.
  • Prizes will be limited to one per person, per household.

INDICATION

  • FINTEPLA is a prescription medicine used to treat seizures associated with Dravet syndrome in patients 2 years of age and older.
  • FINTEPLA is a federally controlled substance (C-IV) because it contains fenfluramine. Keep FINTEPLA in a safe place to prevent misuse, abuse, and protect it from theft. Never give your FINTEPLA to anyone else, because it may harm them. Selling or giving away this medicine is against the law. Tell your healthcare provider if you have abused or been dependent on alcohol, prescription medicines, or street drugs.
  • It is not known if FINTEPLA is safe and effective in children less than 2 years of age.

IMPORTANT SAFETY INFORMATION

FINTEPLA can cause serious side effects, including:

1.    Problems with the valves in the heart (valvular heart disease) and high blood pressure in the arteries of the lungs (pulmonary arterial hypertension) have been associated with fenfluramine, the active ingredient in FINTEPLA. Your healthcare provider will do a test called an echocardiogram to check your heart and for high blood pressure in the arteries of the lungs before you start taking FINTEPLA, again every 6 months during treatment, and one time 3 to 6 months after you take your last dose of FINTEPLA.

Call your healthcare provider right away if you develop any of these signs and symptoms of heart or lung problems during treatment with FINTEPLA:

  • shortness of breath
  • tiredness or weakness, especially with increased activity
  • lightheadedness or fainting
  • swollen ankles or feet
  • chest pain
  • sensations of a rapid, fluttering heartbeat (palpitations)
  • irregular pulse
  • bluish color of your lips and skin (cyanosis)

Because of the risk of heart valve problems and pulmonary arterial hypertension, FINTEPLA is only available through a restricted program called the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS) Program. Before you or your child receives FINTEPLA, your healthcare provider or pharmacist will make sure you understand how to take FINTEPLA safely. If you have any questions about FINTEPLA, ask your healthcare provider, visit www.FinteplaREMS.com, or call 1-877-964-3649.

2.    Decreased appetite and decreased weight. Decreased appetite and decreased weight are both serious and common side effects.

  • Your weight should be checked regularly during your treatment with FINTEPLA.
  • Your healthcare provider may need to make changes to your FINTEPLA dose if your weight decreases. In some cases, FINTEPLA may need to be stopped.

3.    Sleepiness, sedation, and lack of energy (lethargy). These are both serious and common side effects of FINTEPLA. Taking FINTEPLA with central nervous system (CNS) depressants, including alcohol, may increase sleepiness. Do not drive, operate heavy machinery, or do other dangerous activities until you know how FINTEPLA affects you.

4.    Like all other antiepileptic drugs, FINTEPLA may cause suicidal thoughts or actions in a very small number of people (about 1 in 500).

Call your healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you:

  • thoughts about suicide or dying
  • new or worse anxiety
  • trouble sleeping (insomnia)
  • acting on dangerous impulses
  • attempts to commit suicide
  • feeling agitated or restless
  • new or worse irritability
  • an extreme increase in activity and talking (mania)
  • new or worse depression
  • panic attacks
  • acting aggressive, being angry or violent
  • other unusual changes in behavior or mood

How can I watch for early symptoms of suicidal thoughts and actions?

  • Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.
  • Keep all follow-up visits with your healthcare provider as scheduled.



    Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.

5.    Do not stop taking FINTEPLA without first talking to your healthcare provider.

Stopping a seizure medicine such as FINTEPLA can suddenly cause you to have seizures more often or seizures that do not stop (status epilepticus).

Call your healthcare provider between visits as needed, especially if you are worried about symptoms.

Do not take FINTEPLA if you:

  • are allergic to fenfluramine or any of the ingredients in FINTEPLA. See below for a complete list of ingredients in FINTEPLA.
  • are taking or have stopped taking medicines called monoamine oxidase inhibitors (MAOI), serotonin agonists, or serotonin reuptake inhibitors in the last 14 days. This may cause a serious or life-threatening problem called serotonin syndrome. If you are not sure whether or not you are taking one of these medicines, contact your healthcare provider.

Before taking FINTEPLA, tell your healthcare provider about all of your medical conditions, including if you:

  • have heart problems
  • have or have had weight loss
  • have or have had depression, mood problems, or suicidal thoughts or behavior
  • have liver problems
  • have kidney problems
  • are pregnant or plan to become pregnant. Tell your healthcare provider right away if you become pregnant while taking FINTEPLA. You and your healthcare provider will decide if you should take FINTEPLA while you are pregnant.
    • If you become pregnant while taking FINTEPLA, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by calling 1-888-233-2334 or go to www.aedpregnancyregistry.org. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy.
  • are breastfeeding or plan to breastfeed. It is not known if FINTEPLA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking FINTEPLA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

How should I take FINTEPLA?

  • Read the Instructions for Use for information on the right way to use FINTEPLA.
  • Take FINTEPLA exactly as your healthcare provider tells you to take it.
  • Your healthcare provider will tell you how much FINTEPLA to take and when to take it.
  • FINTEPLA may be taken with or without food.
  • Measure your dose of FINTEPLA using the dosing syringe that is provided by the pharmacy. Do not use a household teaspoon or tablespoon.
  • FINTEPLA can be given through gastric and nasogastric feeding tubes.

What should I avoid while taking FINTEPLA?

  • Do not drive, operate heavy machinery, or do other dangerous activities until you know how FINTEPLA affects you. FINTEPLA may cause you to feel sleepy.

What are the possible side effects of FINTEPLA?

FINTEPLA may cause serious side effects, including:

  • See «FINTEPLA can cause serious side effects» above,
    • Serotonin syndrome. Serotonin syndrome is a life-threatening problem that can happen in people taking FINTEPLA, especially if FINTEPLA is taken with certain other medicines including: anti-depressant medicines called SSRIs, SNRIs, TCAs, and MAOIs; tryptophan; lithium; antipsychotics; St. John’s Wort; Dextromethorphan; tramadol.

      Call your healthcare provider right away if you have any of the following symptoms of serotonin syndrome:
      • mental status changes such as seeing things that are not there (hallucinations), agitation, or coma
      • changes in blood pressure
      • tight muscles
      • fast heartbeat
      • nausea, vomiting, diarrhea
      • high body temperature
      • trouble walking
    • High blood pressure (hypertension). Hypertension is both a serious and common side effect. FINTEPLA can cause your blood pressure to increase even if you have never had high blood pressure before. Your healthcare provider will check your blood pressure while you are taking FINTEPLA.
    • Increased pressure in your eyes (glaucoma). Symptoms of glaucoma may include:
      • red eyes
      • seeing halos or bright colors around lights
      • nausea or vomiting
      • decreased vision
      • eye pain or discomfort
      • blurred vision

If you have any of these symptoms, call your healthcare provider right away.

    • The most common side effects of FINTEPLA include:
      • diarrhea
      • low energy
      • respiratory infection
      • tiredness
      • fever
      • constipation
      • abnormal echocardiogram
      • problems with movement, balance, and walking
      • increased drooling
      • infection
      • vomiting
      • falls
      • seizures that do not stop
      • weakness

These are not all the possible side effects of FINTEPLA. For more information, ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1–800–FDA–1088.

Keep FINTEPLA and all medicines out of the reach of children.

General information about the safe and effective use of FINTEPLA.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use FINTEPLA for a condition for which it was not prescribed. Do not give FINTEPLA to other people, even if they have the same symptoms that you have. It may harm them.

What are the ingredients in FINTEPLA?

Active ingredient: fenfluramine hydrochloride

Inactive ingredients: cherry flavor, citric acid, ethylparaben, hydroxyethylcellulose, methylparaben, potassium citrate, sucralose, and water. 

FINTEPLA contains no ingredient made from gluten-containing grain (wheat, barley, or rye).    

Please see Medication Guide and full Prescribing Information, including Boxed Warning, for additional information about FINTEPLA.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/zogenix-launches-dravet-syndrome-community-photo-sharing-charitable-campaign-and-contest-to-benefit-the-dravet-syndrome-foundation-and-the-epilepsy-foundation-301295348.html

SOURCE Zogenix